Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed

By | May 8, 2014

Scalper1 News

Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant’s stock rose fractionally on the stock market today. Valeant reported earnings of $1.76 a share, up 35% from the year-earlier quarter and beating analysts’ consensus by 4 cents, according to Thomson Reuters. Sales rose 77% to $1.89 billion, a bit short of Scalper1 News

Scalper1 News